Celgene's most recent trend suggests a bullish bias. One trading opportunity on Celgene is a Bull Put Spread using a strike $105.00 short put and a strike $95.00 long put offers a potential 13.77% return on risk over the next 30 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $105.00 by expiration. The full premium credit of $1.21 would be kept by the premium seller. The risk of $8.79 would be incurred if the stock dropped below the $95.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Celgene is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Celgene is bullish.
The RSI indicator is at 62.92 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Celgene
Use Caution on Celgene, Going Long Is for the Aggressive and Experienced
Mon, 18 Dec 2017 20:37:00 +0000
This is the kind of activity you see at a climax low.
Gilead Sciences’ Valuation in December 2017
Mon, 18 Dec 2017 20:21:56 +0000
Gilead Sciences (GILD), a leading biopharmaceutical company headquartered in California, is involved in discovering, developing, and commercializing various innovative medicines.
ETFs with exposure to Celgene Corp. : December 18, 2017
Mon, 18 Dec 2017 20:09:01 +0000
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Celgene Corp. Here are 5 ETFs with the largest exposure to CELG-US. Comparing the performance and risk of Celgene Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name … Read more
(Read more…)
The 5 Best-Selling Drugs of 2017
Mon, 18 Dec 2017 12:03:00 +0000
Autoimmune-disease and cancer drugs ruled yet again.
Beware: Price Wars For Big Pharma, Biotech Companies On Horizon
Fri, 15 Dec 2017 18:20:17 +0000
The FDA could further pressure generic drugmakers in 2018 by continuing along its path of increased generic approvals.
Related Posts
Also on Market Tamer…
Follow Us on Facebook